News & Updates

Combination treatment with abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) as initial therapy, compared with NSAI alone, helps extend survival in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer, results of the MONARCH 3 study have shown.

A novel artificial intelligence (AI) classifier can detect hepatocellular carcinoma (HCC) signatures in routine blood tests up to 1 year before clinical diagnosis, as shown in a study from Hong Kong.

Patients with gastrointestinal large cell neuroendocrine carcinoma (GILCNEC) show varying prognosis depending on the site of the primary tumour, suggests a study. Unfortunately, there remains no standardized consensus guidelines to manage GILCNEC.